S 15261

Drug Profile

S 15261

Latest Information Update: 26 Oct 2006

Price : $50

At a glance

  • Originator Servier
  • Class Antihyperglycaemics; Fluorenes; Insulin sensitisers
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 26 Oct 2006 Discontinued - Phase-II for Type-2 diabetes mellitus in France (unspecified route)
  • 09 May 2003 Phase-II clinical trials in Type-2 diabetes mellitus in France (unspecified route)
  • 15 May 2001 A study has been added to the pharmacodynamics and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top